Coala Life Q4 2022 initial take: Optimistic outlook - Redeye

Redeye comments on Coala Life’s Q4’22 report, in which sales increased by c80% over the previous quarter. OPEX was impacted by one-time expenditures, primarily related to regulatory concerns but also resulting from Coala's extended offer in the United States. Given the indication of product-market fit in the US, with a reported ARR of USD4.6m for February '23, we anticipate a fast commercial ramp-up throughout '23. With the recent equity issue dilution as a backdrop, we expect our Base Case (SEK14) to be reduced by a least 75%.

Länk till analysen i sin helhet: https://www.redeye.se/research/891809/coala-life-q4-2022-initial-take-optimistic-outlook?utm_source=finwire&utm_medium=RSS